GERN Geron Corporation Biopharmaceutical

[greencat]

GERN making a high consolidation pattern. It could break this consolidation and make a nice move to the upside.

BUSINESS SUMMARY
Geron Corporation, a biopharmaceutical company, develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. The company develops a range of anti-cancer therapies, including anti-cancer therapies based on telomerase inhibitors, telomerase therapeutic vaccines, and telomerase-based oncolytic viruses, and diagnostics based on telomerase detection. Its products include GRN163 and GRN163L, which are telomerase inhibitors for the treatment of chronic lymphocytic leukemia, solid tumors, non-small cell-lung cancer, and multiple myeloma, which are in phase I trial; and GRNVAC1, a telomerase cancer vaccine for the treatment of acute myelogenous leukemia. Geron Corporation also develops human embryonic stem cell-based therapeutics, with its spinal cord injury treatment. The company has research, development, and commercialization license agreement with Merck & Co., Inc. to use telomerase in non-dendritic cell cancer vaccines. Geron Corporation was founded in 1990 and is based in Menlo Park, California.

Shares Outstanding5: 79.17M
Float: 78.66M
% Held by Insiders1: 0.78%
% Held by Institutions1: 26.10%
Shares Short (as of 12-Jan-09)3: 8.54M
Short Ratio (as of 12-Jan-09)3: 11
Short % of Float (as of 12-Jan-09)3: 10.90%
Shares Short (prior month)3: 8.43M

Income Statement
Revenue (ttm): 6.95M
Revenue Per Share (ttm): 0.09
Qtrly Revenue Growth (yoy): -67.50%
Gross Profit (ttm): 7.62M
EBITDA (ttm): -61.54M
Net Income Avl to Common (ttm): -60.85M
Diluted EPS (ttm): -0.79
Qtrly Earnings Growth (yoy): N/A


Balance Sheet
Total Cash (mrq): 174.34M
Total Cash Per Share (mrq): 2.202
Total Debt (mrq): 0
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 20.95
Book Value Per Share (mrq): 2.273


Cash Flow Statement
Operating Cash Flow (ttm): -34.06M
Levered Free Cash Flow (ttm): -43.34M

[WeatherCat]

THERE'S HUGE NEWS THIS AFTERNOON FOR STEM CELL PLAYS...


WASHINGTON (CNN) – CNN has learned that President Obama is planning to sign at least one executive order on Monday that will overturn Bush-era policy that limited the types of embryonic stem cell research that can receive federal tax dollars, according to administration officials familiar with the deliberations.

Obama's move will be hailed by advocates for those suffering from a host of diseases ranging from diabetes to Parkinson's disease, who believe that an expansion of stem cell research could leads to all kinds of medical progress and help eradicate various debilitating diseases. But many conservatives object to the destruction of human embryos because they contend it ends a human life.

The officials said the administration is planning a Monday event at the White House in which Obama will overturn an executive order signed by former President George W. Bush in August 2001 that barred the National Institutes of Health from funding research on embryonic stem cells beyond using 60 cell lines that existed at the time he signed that order.

Bush also twice vetoed legislation — in July 2006 and June 2007 — that would have expanded federally funded embryonic stem cell research. At the time, Bush said that because of scientific advances researchers could conduct groundbreaking research without destroying human embryos.

[greencat]

GERN with a W pattern. It should move past old highs.

GERN Chart